Literature DB >> 16784856

Tubeimoside V (1), a new cyclic bisdesmoside from tubers of Bolbostemma paniculatum, functions by inducing apoptosis in human glioblastoma U87MG cells.

Guang Cheng1, Yun Zhang, Xiang Zhang, Hai-Feng Tang, Wei-Dong Cao, Da-Kuan Gao, Xi-Ling Wang.   

Abstract

Malignant glioblastoma is one of the most common malignant tumors in the neurological system. Tubeimoside V (1), a new cyclic bisdesmoside from tubers of Bolbostemma paniculatum, appears to exhibit various biological activities, including antitumor effect, but the function and mechanism of this new agent on glioblastoma cells has not previously been determined. In the present study, we investigated the proliferation change of human glioblastoma U87MG cells exposured to different concentrations (0.9-14.8 microM) of Tubeimoside V (1) for a certain time. The results showed that Tubeimoside V (1) significantly suppressed U87MG cell proliferation in a time- and dose-dependent manner (IC(50) = 3.6 microM). Flow cytometric analysis of DNA in U87MG cells showed that Tubeimoside V (1) induces the prominent appearance of a sub-G1 peak in the cell cycle suggestive of apoptosis. Furthermore, U87MG cells' treatment with Tubeimoside V (1) resulted in nuclear condensation with apoptotic bodies observed by both fluorescence and electron microscopy. The result of annexin V/PI assay showed that phosphatidylserine externalization began after treatment, and then increased in the following 24h. Molecular changes explored through Western-blot staining showed Tubeimoside V (1) decreased the expression levels of Bcl-2 protein and increased the expression levels of Bax protein. The novel findings suggest that the cytotoxic actions of Tubeimoside V (1) toward U87MG cells result from the induction of cell apoptosis. Overall, our data demonstrate that Tubeimoside V (1) is an efficient apoptotic killing agent of glioblastoma cells and suggest that this mechanism may play a critical role in anti-tumor chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784856     DOI: 10.1016/j.bmcl.2006.06.020

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Tubeimoside-1 induces glioma apoptosis through regulation of Bax/Bcl-2 and the ROS/Cytochrome C/Caspase-3 pathway.

Authors:  Geng Jia; Qiang Wang; Rong Wang; Danni Deng; Lian Xue; Naiyuan Shao; Yi Zhang; Xiwei Xia; Feng Zhi; Yilin Yang
Journal:  Onco Targets Ther       Date:  2015-01-30       Impact factor: 4.147

2.  Total saponins of Bolbostemma paniculatum (maxim.) Franquet exert antitumor activity against MDA-MB-231 human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway.

Authors:  Jian-Wei Dou; Rong-Guo Shang; Xiao-Qin Lei; Kang-Le Li; Zhan-Zi Guo; Kai Ye; Xiao-Juan Yang; Yu-Wei Li; Yun-Yun Zhou; Jia Yao; Qian Huang
Journal:  BMC Complement Altern Med       Date:  2019-11-08       Impact factor: 3.659

3.  Systems Pharmacology-Based Identification of Mechanisms of Action of Bolbostemma paniculatum for the Treatment of Hepatocellular Carcinoma.

Authors:  Lan-Lan Wang; Chen Liao; Xiao-Qiang Li; Rong Dai; Qing-Wei Ren; Hai-Long Shi; Xiao-Ping Wang; Xue-Song Feng; Xu Chao
Journal:  Med Sci Monit       Date:  2021-01-13

Review 4.  Chinese endemic medicinal plant Bolbostemma paniculatum (Maxim.) Franquet: A comprehensive review.

Authors:  Yujiao Zhou; Junyu Liu; Jianqiong Zhang; Yi Xu; Wangni Li; Pang Gao; Yanghuan Xing; Lehong Huang; Xuhua Qin; Shenrui Jin
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

Review 5.  A Review of Medicinal Plants of the Himalayas with Anti-Proliferative Activity for the Treatment of Various Cancers.

Authors:  Hailemeleak Regassa; Anuradha Sourirajan; Vikas Kumar; Sadanand Pandey; Deepak Kumar; Kamal Dev
Journal:  Cancers (Basel)       Date:  2022-08-12       Impact factor: 6.575

6.  Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model.

Authors:  Yuan Gu; Christina Körbel; Claudia Scheuer; Anca Nenicu; Michael D Menger; Matthias W Laschke
Journal:  Oncotarget       Date:  2016-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.